UK MHRA approval for "FINASTERIDE 5 MG TABLETS ".easy payday loans and secure !

Approval from UK Medicines and Healthcare products Regulatory Agency (MHRA) to manufacture Finasteride 5mg. Finasteride is used for the treatment of urinary problems in men caused by Benign Prostatic Hypertrophy (BPH) or enlargement of the prostate gland.

UK MHRA approval for Amlodipine 5mg and Amlodipine 10mg

Received approval from UK Medicines and Healthcare products Regulatory Agency (MHRA) to market Amlodipine 5mg and Amlodipine 10mg.Following this development, it is the 13th formulation approval received from UK MHRA .

Ghana FDA approval for hypertension drug Atenolol 50 and 100 mg tablet

Ghana FDA approval for hypertension drug Atenolol 50 mg and 100 mg tablet. Atenolol can be used to treat cardiovascular diseases and conditions such as hypertension, coronary heart disease, angina and to treat and reduce the risk of heart complications following heart attack.This is the 9th approval from Ghana FDA.

GMP approval from Australian Therapeutic Goods Administration (TGA)

Bafna received the GMP approval from the Australian Therapeutic Goods Administration (TGA) on manufacturing of both Prescription and Non-Prescription products in the Australian market

UK MHRA approval for Clonazepam 0.5 mg and 2 mg

In July 2010 we received site approval for Clonazepam 0.5 mg and 2 mg tablets from UK, MHRA.

National Level Entrepreneurship Excellence Award

UK MHRA approval for Clonazepam 0.5 mg and 2 mg In July 2010 we received site approval for Clonazepam 0.5 mg and 2 mg tablets from UK, MHRA. National Level Entrepreneurship Excellence Award Mr. Bafna Mahaveer Chand, Chairman & Managing Director, has been conferred by SME with the National Level Entrepreneurship Excellence Award in the manufacturing sector by Mr. C.B. Bhave, Chairman, SEBI.

UK MHRA Approval for Loperamide and Paracetamol

May 2010 we received Site Approval for Loperamide capsules and Paracetamoltablets by UK, MHRA.

GMP Approval from Ethiopias DACA

Bafna Pharmaceuticals, has received the Good Manufacturing Practices (GMP) approval from Ethiopia's Drug Administration and Control Authority (DACA) for its non-betalactam facility. Following the certification, Bafna Pharma expects to tap a huge geography of Africa.

Inauguration Of R&D facility

April 2010, saw the dawn of the state-of-art Research & Development Centre (R&D) which was inaugurated by Mr. Mike Nithavrianakis, the British Deputy High Commissioner to Southern India with Mr.Dhiru Somaiya of Somex Pharma U.K, and Mr. Amit Patel of Auden Meckenzie groups U.K.

UK MHRA Approval for Clarithromycin Tablets Loperamide Capsules Paracetamol Tablets

February 2010 brought us approval of CLARITHROMICIN tablets

IDMA Gold Quality Excellence Award

In January 2010 Bafna received the prestigious GOLD QUALITY EXCELLENCE AWARD from IDMA (Indian Drug Manufacturers Association).

UK MHRA Approval for SIMVASTATIN 10 and 20 mg

In January 2010 granted approval of SIMAVASTATIN 10 and 20 mg tablets from UK, MHRA.

UK MHRA Approval for CLONIDINE

In January 2010 granted approval of CLONIDINE tablets from UK, MHRA.

OLMEBAF First time in Srilanka

In November 2009 Bafna became the first company to launch the first brand of Olmesartan tablets in Sri Lanka - OLMEBAF.